Paper Details

  1. Home
  2. Paper Details

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.

Author: BabuK Suresh, MorjariaJaymin B, PrakashAnoop

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discusses inhaled glycopyrronium bromide, a long-acting muscarinic antagonist, for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrronium has shown similar efficacy to tiotropium, with a low incidence of muscarinic side effects. The review also highlights QVA149, a combination of glycopyrronium bromide and indacaterol maleate, which has been approved as a once-daily maintenance therapy for COPD. QVA149 has demonstrated significant improvements in lung function compared to placebo, glycopyrronium, and tiotropium, making it a safe treatment option for patients with moderate to severe COPD.
Paper Details　
Original Abstract of the Article :
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with COPD. Phase...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293295/

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of COPD: Inhaled Glycopyrronium Bromide Offers New Hope

Chronic obstructive pulmonary disease (COPD) is a relentless desert of lung function challenges. This study explores the therapeutic potential of inhaled glycopyrronium bromide, a long-acting muscarinic antagonist, for managing COPD. The authors review the evidence from Phase III trials, highlighting its efficacy in producing rapid and sustained bronchodilation and its favorable safety profile. The study also explores the benefits of a fixed-dose combination of glycopyrronium bromide with indacaterol maleate (QVA149) as a once-daily maintenance therapy for patients with COPD.

A New Oasis: Inhaled Glycopyrronium Bromide Shows Promise in COPD Treatment

This research unveils the potential of inhaled glycopyrronium bromide as a valuable treatment for COPD. The study's findings demonstrate its efficacy in improving lung function and its favorable safety profile, suggesting a promising alternative for managing this chronic respiratory condition.

Easing the Journey: Glycopyrronium Bromide's Potential Benefits for COPD Patients

This research offers a glimmer of hope for individuals battling COPD. Inhaled glycopyrronium bromide, alone or in combination with indacaterol maleate (QVA149), shows promise in improving lung function and reducing symptoms, potentially enhancing the quality of life for COPD patients.

Dr. Camel's Conclusion

This study provides a comprehensive overview of the therapeutic potential of inhaled glycopyrronium bromide in managing COPD. The findings demonstrate its efficacy in producing bronchodilation and its favorable safety profile, suggesting a promising alternative for managing this chronic respiratory condition. The study also explores the potential benefits of combining glycopyrronium bromide with indacaterol maleate (QVA149), offering a potential pathway for more effective and convenient treatment options.

Date :
  1. Date Completed 2015-09-15
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25609944

DOI: Digital Object Identifier

PMC4293295

Related Literature

Article Analysis
・Side Effects of glycopyrrolate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.